Literature DB >> 19118148

HIF in kidney disease and development.

Lakshman Gunaratnam1, Joseph V Bonventre.   

Abstract

Tissue hypoxia is a pathologic feature of many human diseases including cancer, myocardial infarction, stroke, and kidney disease. An evolutionarily conserved oxygen-sensing mechanism enables cells to adapt and maintain homeostasis under hypoxic conditions by transcriptional activation of a host of genes that mediate metabolic adaptation, angiogenesis, energy conservation, erythropoiesis, and cell survival. The hypoxia-inducible factors (HIFs) comprise a family of oxygen-sensitive basic helix-loop-helix proteins that control the cellular transcriptional response to hypoxia. Inappropriate activation of the HIF system is linked to the development and/or progression of many human malignancies including clear cell renal cancer. HIFs are now postulated to play contrasting protective and pathogenic roles in acute and chronic kidney diseases, respectively. In this review, we discuss the mechanisms of oxygen sensing in renal cells and highlight the role of hypoxia and HIF activation under physiologic conditions and in renal development as well as in acute and chronic kidney diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118148     DOI: 10.1681/ASN.2008070804

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  56 in total

1.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Authors:  Amandine Viau; Khalil El Karoui; Denise Laouari; Martine Burtin; Clément Nguyen; Kiyoshi Mori; Evangéline Pillebout; Thorsten Berger; Tak Wah Mak; Bertrand Knebelmann; Gérard Friedlander; Jonathan Barasch; Fabiola Terzi
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

Review 2.  Cellular and molecular mechanisms of renal fibrosis.

Authors:  Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

Review 3.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease.

Authors:  Imari Mimura; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

4.  Impaired wound healing in hypoxic renal tubular cells: roles of hypoxia-inducible factor-1 and glycogen synthase kinase 3β/β-catenin signaling.

Authors:  Jianping Peng; Ganesan Ramesh; Lin Sun; Zheng Dong
Journal:  J Pharmacol Exp Ther       Date:  2011-10-18       Impact factor: 4.030

5.  MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury.

Authors:  Kirti Bhatt; Qingqing Wei; Navjotsingh Pabla; Guie Dong; Qing-Sheng Mi; Mingyu Liang; Changlin Mei; Zheng Dong
Journal:  J Am Soc Nephrol       Date:  2015-01-13       Impact factor: 10.121

6.  The effect of altitude change on anemia treatment response in hemodialysis patients.

Authors:  M Alan Brookhart; Brian D Bradbury; Jerry Avorn; Sebastian Schneeweiss; Wolfgang C Winkelmayer
Journal:  Am J Epidemiol       Date:  2011-02-23       Impact factor: 4.897

7.  Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis.

Authors:  Franziska Theilig; Anne Kathrin Enke; Brigitte Scolari; Danny Polzin; Sebastian Bachmann; Robert Koesters
Journal:  Am J Pathol       Date:  2011-09-15       Impact factor: 4.307

8.  Hypoxia-inducible factor-1α activation improves renal oxygenation and mitochondrial function in early chronic kidney disease.

Authors:  Joanna L Thomas; Hai Pham; Ying Li; Elanore Hall; Guy A Perkins; Sameh S Ali; Hemal H Patel; Prabhleen Singh
Journal:  Am J Physiol Renal Physiol       Date:  2017-03-22

Review 9.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 10.  Acute kidney injury and chronic kidney disease: From the laboratory to the clinic.

Authors:  David A Ferenbach; Joseph V Bonventre
Journal:  Nephrol Ther       Date:  2016-03-10       Impact factor: 0.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.